Skip to main content

Sofinnova Partners — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

148
Companies
$5.4B
Total invested
$45.1M
Avg. check
24
Industries
Biotechnology 17Health Care 12Medical 11Life Science 7Pharmaceutical 4Medical Device 4+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 148
Redx Pharma
May 2022

Redx Pharma is a drug discovery and development company.

Biotechnology · Macclesfield$43.6M Post-IPO Equity
Werewool
May 2023

Werewool develops a fiber development platform to create biodegradable fibers.

Industrial · New York$3.7M Seed
LimFlow SA
April 2022

LimFlow SA is a venture-backed medical device company.

Emergency Medicine · Paris$39.3M Series D
AFYREN
April 2026

AFYREN is a green chemistry company that produces biobased, low-carbon carboxylic acids through sustainable fermentation technology.

Biotechnology · Saint-beauzire$3.5M Grant
Alia Therapeutics
April 2023

Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.

Biotechnology · Trento$4.8M Seed
Nuage Therapeutics
March 2023

Nuage Therapeutics engages in developing drugs which target proteins in disordered regions for challenging indications faced by patients.

Biopharma · Barcelona$12.9M Seed
GenSight Biologics
March 2026

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

Biotechnology · Paris$2.0M Post-IPO Equity
DNA Script
February 2025

DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.

Biotechnology · Le Kremlin-bicêtre$4.7M Grant
Bon Vivant
February 2026

A French biotechnology company that uses precision fermentation to produce real dairy products, accessible to everyone.

Biotechnology · Lyon$29.4M Series A
Moon Surgical
February 2025

Moon Surgical develops a new category of robotic surgery that enhances existing clinical practice with collaborative and adaptive robotics.

Medical · ParisUndisclosed
Hemab
October 2025

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

Biotechnology · Copenhagen$157.0M Series C
Elevara Medicine
October 2025

Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.

Biotechnology · London$70.0M Series A
MISSION Therapeutics
October 2025

MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.

Biotechnology · Cambridge$13.3M Venture - Series Unknown
NanoPhoria
October 2025

NanoPhoria develops non-viral, nano-delivery systems for cardiovascular treatments, focusing on inhalable biologics.

Analytics · Milan$97.8M Series A
Galvanize Therapeutics
September 2025

Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.

Health Care · San Carlos$100.0M Series C
Actithera
July 2025

Actithera is a molecular radiotherapeutic company that develops radioligand therapies.

Biotechnology · Oslo$75.5M Series A
ENYO Pharma
June 2025

ENYO Pharma is a biopharmaceutical company based in Lyon, France.

Biopharma · Lyon$6.9M Series C
GlycoEra
May 2025

GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.

Biotechnology · Schlieren$130.0M Series B
SafeHeal
April 2025

SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.

Health Care · Paris$39.9M Series C
Latent Labs
February 2025

We are making biology programmable to transform health and sustainability for the benefit of all.

Artificial Intelligence (AI) · London$40.0M Series A
Berry Street
February 2025

Berry Street offers treatment for disordered eating, heart health, PCOD, liver disease, women's health, sports nutrition, and diabetes.

Fitness · New York$50.0M Series B
Leucid Bio
February 2025

Leucid is progressing novel cart therapies that produce a better and more durable response.

Biotechnology · London$8.9M Series A
Freya Biosciences
November 2024

Freya Biosciences is a clinical-stage women's health company pioneering a new class of microbial immunotherapies.

Life Science · Boston$11.8M Series A
Elicit Plant
November 2024

Elicit Plant is an agro-biotech company thatfocuses on enhancing the resilience of crops under drought conditions through natural processes.

Agriculture · Vilhonneur$48.0M Series B

Where Sofinnova Partners invests

Biotechnology17
Health Care12
Medical11
Life Science7
Pharmaceutical4
Medical Device4

About Sofinnova Partners's portfolio

How many companies has Sofinnova Partners invested in?

Sofinnova Partners has invested in 148 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Sofinnova Partners invest in?

Sofinnova Partners's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Pharmaceutical. The firm invests across 24 different industry categories.

What is Sofinnova Partners's largest investment?

Among tracked funding rounds, Hemab received $157.0M in a Series C round. Sofinnova Partners's total known invested capital is $5.4B.

What is the average investment size for Sofinnova Partners?

Sofinnova Partners's average investment size is $45.1M across its portfolio of 148 companies.

What are Sofinnova Partners's most recent investments?

Recent Sofinnova Partners portfolio additions include Redx Pharma, Werewool, LimFlow SA, AFYREN, Alia Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 148 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →